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Abstract
Purpose: Clinical target volumes (CTV) for radiotherapy (RT) in esophageal cancer (EC) are based on standard expansions
of primary tumor volume. Data is needed to define regions at highest risk for occult disease, based on histology and
location of the primary tumor. We therefore reviewed PET scans in EC patients to characterize the location of FDG-avid
lymph node metastases (LNM).
Materials and methods: We identified 473 EC patients with reviewable pre-treatment PET-CT scans. Tumors
were classified by histology and location; 85% were distal or GE junction tumors and 71% were adenocarcinoma. FDG-
avid LNM were classified using standard radiographic nodal atlases, and distances from primary tumor to paraesophageal
LNM were also measured.
Results: The most common LNM in upper EC were supraclavicular, retrotracheal and paratracheal. The most common
LNM in lower EC were paraesophageal and in the gastrohepatic space. Overall, 55% of paraesophageal LNM
were adjacent to primary tumor. Of upper esophageal tumors with paraesophageal LNM, 87% were adjacent
to the tumor and none were >6 cm from tumor. However, 57% of lower esophageal tumors with paraesophageal
LNM had non-adjacent paraesophageal nodes, 24% of which were >8 cm from the tumor.
Conclusion: A more data-driven and individualized approach to CTV delineation could improve the therapeutic ratio
of RT in esophageal cancer. These results can guide CTV delineation by indicating the potential distribution of nodal
involvement in esophageal cancer.
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Introduction
An estimated 482,300 new cases of esophageal cancer
occured worldwide in 2014, with 18,170 in the United
States. Because of the extensive network of esophageal
lymphatics, metastasis to regional lymph nodes occurs
early and frequently, contributing to an 85% mortality
rate. Five-year survival for all patients with esophageal
cancer over the past decade is estimated at 19%, which
is significantly improved since the 1970s but still leaves
much to be desired [1].
Both neoadjuvant and definitive chemoradiotherapy
have become well-established standards of care in the
treatment of esophageal cancer (EC) [2–4]. Currently,
radiation treatment (RT) fields for EC are quite large as
they are based on simple geometric expansions of the
primary tumor volume to limit locoregional lymph node
metastasis (LNM). For example, current clinical trials
typically define the clinical target volume (CTV) by
calling for a 4 cm longitudinal expansion and 1.5 cm
radial expansion from the gross tumor volume (GTV)
[5, 6].
However, data from esophageal squamous cell cancer
has generated controversy regarding the effectiveness of
an expanded CTV in preventing either local recurrence
or LNM, and it is unclear whether such large and
standardized fields are always necessary, including for
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esophageal adenocarcinomas [7–9]. A more tailored CTV
limited to nodal stations at significant risk could reduce
adverse effects of RT, but data are lacking to guide the
choice of which lymph node regions to include, particularly
for distal esophageal adenocarcinomas.
FDG-PET scans are now standard in the staging of
esophageal cancer because of their ability to detect
metastatic disease, including lymph node metastases
(LNM). Several studies have demonstrated correlation
between LNM indicated on staging PET scans and actual
LNM based on surgical pathology [10, 11]. Therefore,
we reviewed initial staging PET scans in patients with
newly diagnosed esophageal cancer to characterize the
frequency and location of FDG-avid LNM relative to the
primary tumor and radiographic definitions of nodal
stations.
Materials and methods
Institutional review and privacy boards approved this
study, and patient confidentiality was maintained as re-
quired by the Health Insurance Portability and Account-
ability Act. We then queried institutional databases to
identify all patients receiving preoperative or definitive-
intent RT at our institution for esophageal or gastro-
esophageal junction cancer between June 2007 and January
2014. All patients had confirmation of esophageal adeno-
carcinoma or squamous cell carcinoma on central patho-
logic review. We excluded patients with non-squamous or
non-adenocarcinoma histology, distant metastases, syn-
chronous malignancies, or who did not have a reviewable
PET-CT scan prior to initiation of therapy. In cases where
patients had more than one PET-CT prior to treatment, we
analyzed the most recent one. In total, 473 patients who
met these criteria were analyzed.
Tumor location was classified according to the geo-
metric center of the FDG-avid lesion into the following
categories: cervical (superior to the thoracic inlet); upper
mediastinal (between the thoracic inlet and carina);
lower mediastinal (between the carina and the gastro-
esophageal (GE) junction); and gastroesophageal (any
tumor extending into the GE junction).
Most patients (58%) had PET-CT performed at our
center. In these patients, PET-CT data were acquired on
GE® Discovery PET-CT scanners, and PET images were
reconstructed using an ordered subset expectation
maximization (OSEM) iterative algorithm. CT data were
acquired with 140 kVp and 70 mA, without IV contrast.
All FDG-avid lymph nodes described in the PET-CT
report as at least “suspicious” (>50% probability of being
malignant, according to our institutional standards for
radiology reporting) were recorded and classified using
standard nodal atlases: the International Association for
the Study of Lung Cancer system for thoracic nodes,
and the Japanese Research Society for Gastric Cancer
system for abdominal nodes [12, 13]. The presence or
absence of FDG-avid LNM in each of 28 nodal stations
(12 thoracic and 16 abdominal) was recorded for each
patient.
The rationale for large longitudinal CTV margins is
based, in part, on concern for occult paraesophageal
nodal spread from the primary tumor. Therefore, we
also measured and recorded the longitudinal distance
between the primary tumor and any FDG-avid LNMs
arising in a paraesophageal location (thoracic stations 1,
2, 3P, 4, 7, and 8).
Results
Median patient age was 66 years (range, 28–95), 76%
were male, and 87% were Caucasian. Three-quarters had
stage III tumors, predominantly adenocarcinoma (71%),
with 89% classified as moderately or poorly defined.
Lower thoracic (LT) tumors, defined as being inferior to
the carina, comprised 88% of all tumors (40% lower
mediastinal, 48% gastroesophageal), and were 80% adeno-
carcinomas, while upper thoracic (UT) tumors were 91%
squamous cell carcinoma. Patient characteristics are sum-
marized in Table 1.
FDG-avid LNM were identified in 204 patients (43%),
with 95% having LNM in 3 or fewer stations (range 1–12,
Table 2). LNM distribution and longitudinal distances
from tumor are presented in Tables 3, 4, 5 and Fig. 1
below.
Upper thoracic tumors
UT tumors almost exclusively involved thoracic LNs,
with only 1 out of the 82 LNMs seen in an abdominal
station (1%). There were also a small number of patients
(5% of UT and 1% of LT) with cervical LNM (i.e. above
the supraclavicular region), that were nevertheless con-
sidered regional disease by the treating physicians and
underwent definitive radiotherapy. The most commonly
involved lymph node stations were supraclavicular (level
1, 27% of all involved LN stations in UT tumors), retro-
tracheal (level 3P, 17% of involved stations), lower para-
tracheal (level 4, 13%) and upper paratracheal (level 2,
11%). Supraclavicular (level 1) and paratracheal LNs
(levels 2, 3P and 4) together accounted for 68% of all
involved nodal regions in UT tumors. The vast majority
of paraesophageal LNMs (89%) were at the same axial
level as the primary tumor (i.e. visible on the same axial
CT slice as the primary), and none were >5.3 cm away.
Lower thoracic tumors
LT tumors showed a much wider distribution of LNM
across thoracic and abdominal LNs. The most com-
monly involved lymph node stations were paraesopha-
geal below the carina (level 8, 19% of involved stations)
and those in the gastrohepatic space, including right
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Table 1 Patient characteristics
Total (n) % With FDG-avid LN metastasis % Metastasis rate †
Total patients 473 204 43
- Male 361 76 163 80 45
- Female 112 24 41 20 36
Age at diagnosis
- 20–49 38 8 22 11 58
- 50–59 103 22 44 22 43
- 60–69 156 33 70 34 45
- 70–79 125 26 50 25 40
- 80+ 51 11 18 9 35
Median (range) 66 (28–95) 64 (28–88)
Race
- White 413 87 178 87 43
- Black 24 5 9 4 36
- Asian 18 4 9 4 50
- Other/Not specified 18 4 8 4 44
Tumor stage
- T1 22 5 9 4 41
- T2 59 12 18 9 31
- T3 345 73 148 73 43
- T4 19 4 12 6 63
- n/a 28 6 17 8 61
Tumor differentiation
- well-differentiated 7 1 3 1 43
- moderately-differentiated 219 46 95 47 43
- poorly-differentiated 205 43 94 46 46
- not specified 43 9 12 6 29
Tumor histology
- Adenocarcinoma 338 71 138 68 41
- Squamous Cell 135 29 66 32 49
Tumor location
Upper Thoracic 57 12 31 15 54
Cervical 15 3 3 1 20
- Adenocarcinoma 1 7 1 33 100
- Squamous Cell 14 93 2 67 14
Upper Mediastinal 42 9 28 14 67
- Adenocarcinoma 4 10 2 7 50
- Squamous Cell 38 90 26 93 68
Lower Thoracic 417 88 173 85 41
Lower Mediastinal 188 40 73 36 39
- Adenocarcinoma 124 66 46 63 37
- Squamous Cell 634 34 27 37 42
Gastroesophageal 229 48 100 49 44
- Adenocarcinoma 210 92 89 89 42
- Squamous Cell 19 8 11 11 58
†Metastasis rate is the percentage of total patients in a given category with FDG-avid LNM
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paracardial (level 1), lesser curvature (level 3), and left
gastric nodes (level 7), together comprising 34% of
involved nodes in LT tumors. The remainder of involved
nodes were distributed among all but 7 of the 28
thoracic and abdominal node stations surveyed. Longitu-
dinal distances from LT tumors to paraesophageal LNMs
were greater than for UT, with 58% of paraesophageal
LNMs non-adjacent to the primary tumor. Unlike upper
thoracic tumors, non-adjacent paraesophageal LNMs
were likely to be far from the primary tumor, with 24%
being over 8 cm away (Tables 3, 4, 5 and Fig. 1).
Discussion
Guidelines for elective nodal irradiation (ENI) in esophageal
cancer were originally developed in an era of two-
dimensional treatment planning, and are therefore still
based on simple geometric expansions of the primary
tumor volume rather than cross-sectional nodal anatomy.
Moreover, these geometric expansions are relatively large,
given the propensity of esophageal cancer to have occult
involvement of regional nodes or to recur in those areas
after local therapy.
With the routine use of CT and PET-CT imaging and
the availability of conformal RT techniques such as
IMRT, radiation oncologists now have the ability to
delineate and selectively deliver RT to CTVs based on
cross-sectional nodal anatomy. However, data is needed
to guide CTV delineation with reference to cross-
sectional imaging in order to maximize the probability
that elective nodal irradiation will be effective in redu-
cing locoregional recurrence. An esophageal contouring
atlas, based on expert consensus, has recently been














Table 3 Longitudinal distance from primary tumor to
paraesophageal lymph node metastases (thoracic stations
1 (supraclavicular), 2 (upper paratracheal), 3P (retrotracheal),
4 (lower paratracheal), 7 (subcarinal), and 8 (paraesophageal,
below the carina)). Note that median distance is 0 for upper
thoracic tumors due to most such lymph nodes being
adjacent to primary tumor
Tumor location Median (cm) Range (cm)
Upper thoracic 0 0–5.3
Lower thoracic 1.52 0–18.5
Table 4 Percentage of all involved thoracic lymph node
stations in upper vs. lower esophageal cancers. (i.e., cervical nodes
represented 5% of the total number of FDG-avid nodal
stations in upper thoracic tumors)
Tumor location
Thoracic nodal stations Upper thoracic Lower thoracic/
GE junction
Cervical 5 1
1 (Supraclavicular) 27 4
2 (Upper paratracheal) 11 2
3A (Prevascular) 5 0
3P (Retrotracheal) 17 5
4 (Lower paratracheal) 13 7
5 (Aortopulmonary window) 2 1
6 (Para-aortic) 1 1
7 (Subcarinal) 5 5
8 (Paraesophageal, below carina) 6 19
9 (Pulmonary ligament) 0 0
10, 11 (hilar) 6 5
Table 5 Percentage of all involved abdominal lymph node
stations in upper vs. lower esophageal cancers. (i.e., cervical nodes
represented 5% of the total number of FDG-avid nodal stations in
upper thoracic tumors)
Tumor location
Abdominal nodal stations Upper thoracic Lower thoracic
1 (Right paracardial) 0 8
2 (Left paracardial) 0 2
3 (Lesser curvature) 0 10
4 (Greater curvature) 0 1
5 (Suprapyloric) 0 0
6 (Infrapyloric) 0 0
7 (Left gastric) 1 16
8 (Common hepatic) 0 2
9 (Celiac) 0 7
10 (Splenic hilum) 0 0
11 (Splenic) 0 2
12 (Hepatoduodenal) 0 2
13 (Posterior pancreatic head) 0 1
14 (Superior mesenteric) 0 0
15 (Middle colic) 0 0
16 (Para-aortic) 0 3
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published and provides guidelines for ENI based upon
the data available, while acknowledging the need for
additional data and the limitations inherent in trying to
generalize the available data to CTV delineation [14]. An
additional CTV atlas, specific to squamous cell carcinoma
of the thoracic esophagus, has also recently been
published [15].
Generally, current clinical practice is to expand the
CTV approximately 3–4 cm longitudinally and 1–2 cm
radially from the GTV as noted above. The practice-
defining CROSS trial, for example, specified a 4 cm
longitudinal PTV expansion from tumor, which corre-
sponds to a 3 cm CTV expansion assuming a typical
1 cm PTV expansion from CTV [16]. In addition, many
practitioners further extend the CTV inferiorly to cover
the celiac axis nodes for LT tumors, and to the supracla-
vicular basins for UT tumors, further expanding the size
of the irradiated field relative to the tumor. In the case
of a distal or GE junction cancer, it is not uncommon
for the CTV to be 10–20 times as large as the GTV,
after standard expansions have been applied. Greater
CTV volumes will inevitably lead to greater volumes of
irradiated normal tissues, including the heart, lungs,
stomach, bowel, and esophagus itself, which in turn
leads to a greater probability for acute and late toxicity.
Therefore, if low-risk nodal regions can be safely
excluded from the CTV, the therapeutic ratio for RT
should increase.
A number of studies report on the pattern of LNM in
esophageal cancer, based on surgical pathologic data.
Two studies from China represent the most significant
efforts to map LNM, based on surgical pathologic data
from patients with thoracic esophageal SCC [6, 17].
However, those results are less relevant to current prac-
tice in the West, where adenocarcinomas arising from
the distal esophagus or GE junction comprise the majority
of EC. A small number of studies have reported pathologic
patterns of lymph node involvement after surgical resec-
tion of GE junction adenocarcinoma [18–20]. These
studies are generally concurrent with our findings that for
distal esophageal and GE junction cancers, the gastrohe-
patic space and paraesophageal nodes are most commonly
involved, and that for UT tumors, metastasis rates to
lower mediastinal and abdominal nodes are low.
Our study expands the knowledge base for patterns of
nodal involvement in a number of ways, however: it is
based on a significantly larger pool of patients than
either the Meier or Dresner studies (and hence is the
largest published dataset of nodal involvement for
esophageal adenocarcinoma, to our knowledge). We also
suggest that PET-CT-based data can be more readily
extrapolated to radiation oncology planning, which is a
CT-based endeavor. For example, determining the radio-
graphic distance between GTV and paraesophageal
nodes cannot be accurately measured from pathologic
data due to artifacts induced by histopathologic processing
and the inability to precisely preserve and record precise
anatomic relationships that existed prior to surgery.
The results of this study provide information on the
potential distribution of LNM in esophageal cancer by
describing the patterns of FDG-avid LNM at the time of
presentation. Though the purpose of ENI is to reduce
nodal relapse by targeting potential occult disease, it is
highly likely that the pattern of occult disease conforms
Fig. 1 Frequency of lymph node station involvement by tumor location. Numbers with asterisks represent abdominal nodal stations. a Upper
thoracic tumor (n = 31). b Lower thoracic tumor (n = 173)
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to the patterns of initial FDG-avid nodal disease
described in this study. To a large extent, our results
confirm the prevailing guidelines for elective nodal
coverage. With upper esophageal cancers, for example,
we found a high rate of supraclavicular nodal involve-
ment. This supports the routine inclusion of the supra-
clavicular nodes in the CTV for tumors arising above
the level of the carina, despite other studies suggesting
no clear role for elective nodal radiation of any kind in
squamous esophageal cancer. Uncertainty persists
regarding the need for inclusion of the anterior medias-
tinal nodes (levels 3A, 5, and 6) in the CTV, however.
We identified some patients with FDG-avid anterior
mediastinal nodes, but collectively they represented less
than 10% of upper esophageal cases.
Our data is unique in allowing us to analyze patterns
of LNM across multiple histologies and subsites of
esophageal cancer, in contrast to the cited studies that
were limited to squamous cell cancers or GE junction
cancers exclusively. We found that the distribution of
LNM was much more circumscribed for upper esophageal
cancers, compared to distal or GE junction cancers. Since
it was rare for upper esophageal cancers to metastasize to
distant para-esophageal nodes, this study suggests that
there is no need for large CTV expansions inferiorly below
the level of the tumor.
The majority of our study population comprised lower
esophageal and GE junction adenocarcinomas, and
further insights can be gleaned from our analysis of this
population. Generally, these patients demonstrated a
greater distribution of LNM among both thoracic and
abdominal stations. Since most distal tumors are adeno-
carcinomas, this is also consistent with the notion that
adenocarcinomas have a more widespread distribution
of potential recurrence compared to squamous cell car-
cinomas. Our data confirms a significant rate of paraeso-
phageal LNM, which supports the existing guidelines for
radial CTV expansions from tumor and esophagus. We
also found clear patterns in abdominal LNM, which is
informative, as traditional guidelines for esophageal
cancer CTV typically do not define the extent of recom-
mended abdominal LN coverage in terms of defined
nodal stations. In particular, it was very common for
LNM to arise in the gastrohepatic space (which corres-
pond to the contiguous stations 1, 3 and 7 in the Japanese
Research Society for the Study of Gastric Cancer classifi-
cation). Therefore, we would strongly recommend the
routine inclusion of these nodal regions in the CTV for
distal esophageal cancers.
On the other hand, we did not identify a high rate of
involvement of the splenic hilar or greater curvature
nodes, which have sometimes been suggested as candi-
dates for inclusion in the CTV for GE junction tumors
[19]. Since inclusion of these nodes significantly
increases the CTV size, and particularly the dose to ra-
diosensitive structures such as the stomach and kidney,
our data provides some reassurance that omission of
those nodal sites should not lead to an excessive rate of
disease recurrence in those sites. It should be noted,
however, that tumors with significant cardia involvement
would have been classified as primary gastric cancers
and therefore excluded from this study.
Another area of controversy is the necessity for celiac
nodal coverage, particularly since this is the most caudal
region considered in esophageal cancer RT and therefore
results in significant enlargement of the CTV. A report
from the MD Anderson Cancer Center indicated that
the rate of celiac nodal recurrence, though not especially
common, appeared high enough to warrant elective
coverage [21]. Though we found that the celiac nodes
were not among the most commonly involved nodes in
distal esophageal tumors, we still observed a high
enough rate that we likewise suggest it be strongly
considered for routine inclusion in the CTV.
Finally, we note that the relationship of paraesophageal
LNM to the primary tumor was not predictable, and that
such LNM could arise far from the primary tumor. The
implications of this observation are not straightforward.
Very large longitudinal CTV expansions could be used
to cover occult paraesophageal nodal involvement. How-
ever, the potential toxicity of radiating such a substantial
length of the thorax and esophagus is high. Therefore,
even though large longitudinal CTV expansions may
treat additional sites of LNM, we conjecture that the
therapeutic ratio of radiotherapy might be maximized by
limiting longitudinal CTV to what is required to encom-
pass the primary tumor alone. The question of optimal
longitudinal CTV expansions deserves further study.
The major limitation of this study is the ability of
PET-CT to accurately identify metastatic lymph nodes.
In general, because FDG-PET only identifies macro-
scopic lymph node disease, PET-based data will under-
state the actual rates of pathologic LN involvement. For
this reason, the rates of nodal involvement reported here
cannot be directly compared to rates derived from
pathologic data. Previous meta-analyses have placed the
sensitivity and specificity of detecting involved lymph
nodes in esophageal cancer with 18FDG PET-CT
between 55–62% and 76–96% respectively [22, 23].
Other studies have reported varying accuracies depending
on tumor type, stage, SUV max, and the location of lymph
node involvement [10, 24–26]. One reason for the rela-
tively lower sensitivity of PET is its limited spatial
resolution, which can make it difficult to distinguish para-
esophageal LNM from adjacent FDG-avid primary tumor.
Though PET-CT alone may not fully reflect the true
nodal stage in an individual patient, our aggregated
PET-based data are still relevant towards the study goal,
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which is to identify the regional nodes at highest relative
risk of involvement for esophageal cancer patients as a
group. Though patterns of locoregional relapse (which
are most likely correlated to occult microscopic disease)
may not mirror the patterns of gross FDG-avid nodal
involvement described here, it is likely that there is some
correlation, and we present this data as a supplement to
existing literature on pathologic nodal involvement and
observed sites of locoregional recurrence. And the fact
that PET underestimates the rate of GTV-adjacent LNM
is less relevant to the question of optimal CTV delinea-
tion, since GTV-adjacent LNM will always be covered as
long as there is sufficient margin on the GTV itself.
With respect to identifying high-risk regional nodes that
would not otherwise be covered with margin on GTV,
our data should be of significant utility.
Overall, this analysis provides a basis for individualized
CTV delineation based on the location of the primary
tumor, and with reference to radiographic nodal stations
rather than standard geometric expansions or bony
anatomy. We propose that the CTV for upper thoracic
tumors routinely include the bilateral supraclavicular
basins and the paraesophageal nodes at the level of the
FDG-avid tumor, but not significantly below. The CTV for
lower thoracic and GE junction tumors should always
include the lymph nodes in the gastrohepatic space, and
likely also the celiac region, in addition to paraesophageal
nodes at the level of FDG-avid tumor. Though distal
esophageal adenocarcinomas have the potential to spread
to multiple other lymph node regions throughout the
abdomen and thorax, it does not appear to do so in a
regular or frequent enough fashion to propose routine
inclusion of other nodal regions besides the ones already
mentioned.
These data and the resulting guidelines, being based
on retrospective data from a single-institution series,
obviously cannot be considered authoritative. However,
they are derived from a significant number of patients
and largely concur with what has been suggested by
existing literature. Similar analyses of other patient
cohorts, particularly at institutions or regions with
different mixes of esophageal cancer histologies and pre-
sentations, will help to strengthen or refine these
conclusions.
Conclusions
A more data-driven and individualized approach to CTV
delineation could improve the therapeutic ratio of RT in
esophageal cancer. These results can guide CTV delinea-
tion by indicating the potential distribution of nodal
involvement in esophageal cancer. Our data identified clear
patterns in abdominal LNM, with frequent involvement of
gastrohepatic and celiac, but not splenic hilar or greater
curvature nodes. Additionally, our study confirms a
significant rate of LNM directly adjacent to paraesophageal
tumors, especially those above the carina. However, the
distance between paraesophageal tumors and LNM was
not predictable, suggesting that large longitudinal CTV
expansions to cover occult LNM may not always be
warranted.
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